Sei Investments Co. Has $986,000 Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Sei Investments Co. trimmed its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 66.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,935 shares of the company's stock after selling 26,041 shares during the period. Sei Investments Co.'s holdings in Dr. Reddy's Laboratories were worth $986,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of RDY. Jane Street Group LLC grew its stake in Dr. Reddy's Laboratories by 2,197.8% in the 1st quarter. Jane Street Group LLC now owns 113,168 shares of the company's stock valued at $8,301,000 after buying an additional 108,243 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Dr. Reddy's Laboratories by 46.9% during the 1st quarter. BNP Paribas Financial Markets now owns 103,259 shares of the company's stock worth $7,574,000 after purchasing an additional 32,958 shares during the last quarter. OLD Mission Capital LLC boosted its stake in Dr. Reddy's Laboratories by 66.2% during the 1st quarter. OLD Mission Capital LLC now owns 47,537 shares of the company's stock valued at $3,487,000 after purchasing an additional 18,930 shares during the period. O Shaughnessy Asset Management LLC grew its holdings in Dr. Reddy's Laboratories by 11.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 62,177 shares of the company's stock valued at $4,561,000 after buying an additional 6,322 shares during the last quarter. Finally, Artemis Investment Management LLP increased its position in Dr. Reddy's Laboratories by 92.6% in the 2nd quarter. Artemis Investment Management LLP now owns 15,600 shares of the company's stock worth $1,189,000 after buying an additional 7,500 shares during the period. 14.02% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Barclays boosted their target price on shares of Dr. Reddy's Laboratories from $81.00 to $87.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 30th.

Dr. Reddy's Laboratories Stock Performance

Dr. Reddy's Laboratories stock traded up $1.09 during trading hours on Tuesday, hitting $78.75. The stock had a trading volume of 135,843 shares, compared to its average volume of 213,789. The company has a 50-day moving average of $81.00 and a two-hundred day moving average of $76.04. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a fifty-two week low of $63.72 and a fifty-two week high of $84.46. The company has a market cap of $13.14 billion, a PE ratio of 19.49, a price-to-earnings-growth ratio of 1.75 and a beta of 0.55.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Saturday, July 27th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.10 by ($0.10). Dr. Reddy's Laboratories had a net margin of 19.28% and a return on equity of 20.32%. The firm had revenue of $919.80 million during the quarter, compared to analyst estimates of $861.68 million. On average, equities research analysts anticipate that Dr. Reddy's Laboratories Limited will post 4.11 EPS for the current fiscal year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.